^
Association details:
Biomarker:TP53 mutation
Cancer:Glioblastoma
Drug:AZD1390 (ATM kinase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

2598 / 11 - AZD1390 radio-sensitizes p53-mutant GBM via disrupting homology directed DNA repair

Published date:
03/09/2022
Excerpt:
IR/AZD1390 treatment resulted in significant survival extension...However, when stratified by TP53 status, combination therapy was significantly more effective...in TP53-mutant PDXs, where all 5 models benefited....